Form 4 for SPRO Spero Therapeutics, Inc.
Accepted 2026-06-25 19:14:32 ET · period of report 2026-06-23 · accession 0001193125-26-283230 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-06-25 19:14 | 2026-06-23 | SPRO | Smith Cynthia | Dir | A - Grant | $0.00 | +10.0K | 85.0K | +13% | $0 |
| D | 2026-06-25 19:14 | 2026-06-23 | SPRO | Smith Cynthia | Dir | A - Grant | $0.00 | +20.0K | 20.0K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-06-23 | A | A | 10,000 | $0.00 | 85,000 | D | — | — | (F1) Consists of restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest on June 23, 2027, subject to the Reporting Person's continued service through the applicable vesting date. |
| 2 | Derivative | Stock Option (right to buy) | 2026-06-23 | A | A | 20,000 | $0.00 | 20,000 | D | $2.15 · — to 2036-06-23 | 20,000 Common Stock | (F2) The shares underlying this option will vest and become exercisable in full on June 23, 2027 subject to the Reporting Person's continued service as a director through the vesting date. |